GlassScriptPhysician profile
David C Campbell
NPI 1811100985
$14,627.67
in general payments reported to CMS, 2019-2025
54 companies · $3,064 in 2025
The $3,064 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,003 · 2020: $1,475 · 2021: $1,879 · 2022: $1,842 · 2023: $2,194 · 2024: $3,171 · 2025: $3,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,429.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,048.19 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,657.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,425.41 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,318.21 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $934.23 | 2019-2025 | |
| Lilly USA, LLC | $807.14 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $633.69 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $503.62 | 2021-2025 | |
| Corium, LLC | $461.13 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $433.09 | 2019-2025 | Trintellix |
| Antares Pharma, INC. | $370.99 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Merck Sharp & Dohme LLC | $364.36 | 2019-2025 | Gardasil 9, Capvaxive, Lagevrio |
| Amgen INC. | $325.67 | 2019-2025 | Otezla, Repatha, Repatha |
| Allergan, INC. | $238.17 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.01 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $226.40 | 2024-2025 | Auvelity, Sunosi |
| Amarin Pharma, INC. | $188.40 | 2019-2022 | |
| Abbott Laboratories | $173.70 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $167.79 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $145.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $133.74 | 2019-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $128.60 | 2022-2023 | Qelbree |
| Eisai INC. | $118.07 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $115.29 | 2023-2024 | Ztlido |
| Kowa Pharmaceuticals America, INC. | $114.61 | 2020-2022 | |
| Medtronic, INC. | $97.21 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $95.95 | 2022 | |
| Corcept Therapeutics | $91.67 | 2024-2025 | Korlym |
| Tolmar, INC. | $89.41 | 2024-2025 | Jatenzo |
| Idorsia Pharmaceuticals US INC | $76.90 | 2023-2024 | Quviviq |
| Adlon Therapeutics L.P. | $72.05 | 2020 | |
| Lundbeck LLC | $68.07 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $59.96 | 2019-2025 | Fanapt |
| Genentech USA, INC. | $55.95 | 2019-2020 | |
| Melinta Therapeutics, LLC | $55.03 | 2019 | |
| Dexcom, INC. | $53.42 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $44.82 | 2025 | |
| Sumitomo Pharma America, INC. | $42.25 | 2024-2025 | Gemtesa |
| Horizon Therapeutics Plc | $42.00 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $41.39 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.11 | 2025 | Caplyta |
| Almatica Pharma LLC | $40.63 | 2023-2024 | Loreev Xr |
| Astellas Pharma US INC | $36.51 | 2020-2024 | Veozah |
| Scynexis, INC. | $35.98 | 2022 | |
| Boston Scientific Corporation | $34.11 | 2019-2025 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $30.59 | 2021 | |
| Harmony Biosciences LLC | $30.06 | 2025 | |
| Daiichi Sankyo INC. | $28.71 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $21.45 | 2021 | |
| Tris Pharma INC | $20.78 | 2023 | Dyanavel Xr |
| Orchard Therapeutics North America | $17.20 | 2024 | Lenmeldy |
| E.R. Squibb & Sons, L.L.C. | $15.23 | 2023 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $12.51 | 2019 | |
| Medicure Pharma INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.